About benitec biopharma - BNTC
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. Its proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.
BNTC At a Glance
Benitec Biopharma, Inc.
3940 Trust Way
Hayward, California 94545
| Phone | 1-510-780-0819 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -45,546,000.00 | |
| Sector | Health Technology | Employees | 24 | |
| Fiscal Year-end | 06 / 2027 | |||
| View SEC Filings |
BNTC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.601 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -8.748 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.002 |
BNTC Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,897,750.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BNTC Liquidity
| Current Ratio | 33.998 |
| Quick Ratio | 33.998 |
| Cash Ratio | 33.699 |
BNTC Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -32.278 |
| Return on Equity | -33.208 |
| Return on Total Capital | -25.62 |
| Return on Invested Capital | -33.116 |
BNTC Capital Structure
| Total Debt to Total Equity | 0.43 |
| Total Debt to Total Capital | 0.429 |
| Total Debt to Total Assets | 0.417 |
| Long-Term Debt to Equity | 0.15 |
| Long-Term Debt to Total Capital | 0.15 |